赛伦生物(688163) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 was ¥75,233,299.21, representing a year-on-year increase of 3.95%[2] - Net profit attributable to shareholders for Q3 2024 was ¥30,639,728.49, an increase of 28.26% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2024 was ¥27,514,141.33, up 37.16% year-on-year[2] - The basic earnings per share for Q3 2024 was ¥0.28, reflecting a 27.27% increase from the previous year[3] - Total operating revenue for the first three quarters of 2024 reached CNY 173,291,573.09, an increase of 4.3% compared to CNY 166,133,808.11 in the same period of 2023[17] - Net profit for the first three quarters of 2024 was CNY 62,947,540.75, representing a 23.9% increase from CNY 50,797,820.53 in the previous year[19] - The total comprehensive income attributable to minority shareholders for Q3 2024 was ¥62,947,540.75, compared to ¥50,797,820.53 in Q3 2023, reflecting an increase of approximately 24.4%[20] - Basic and diluted earnings per share for Q3 2024 were both ¥0.58, up from ¥0.47 in Q3 2023, representing a growth of 23.4%[20] Expenses and Costs - Research and development expenses totaled ¥3,772,620.95 in Q3 2024, a significant decrease of 71.22% year-on-year[3] - Total operating costs decreased to CNY 107,900,485.01, down 3.8% from CNY 111,754,125.92 year-over-year[17] - Research and development expenses for the first three quarters of 2024 were CNY 16,170,774.43, a decrease of 26.9% compared to CNY 22,111,264.41 in the same period of 2023[17] - The company’s sales expenses rose to ¥39,321,198.92, up from ¥36,980,681.37, indicating a 6.3% increase[27] Assets and Liabilities - The total assets at the end of Q3 2024 were ¥1,145,484,498.38, a 1.51% increase from the end of the previous year[3] - As of September 30, 2024, the company's total current assets amounted to approximately RMB 968.14 million, an increase from RMB 948.93 million at the end of 2023, reflecting a growth of about 2.3%[10] - The company's total assets reached RMB 1.15 billion, compared to RMB 1.13 billion at the end of 2023, showing a growth of approximately 1.1%[10] - The company's total liabilities decreased to CNY 31,326,752.16 from CNY 42,631,940.16, reflecting a reduction of approximately 26.5%[16] - The total equity attributable to shareholders increased to CNY 1,114,157,746.22, up from CNY 1,085,840,605.47, marking a growth of 2.6%[16] - The total current assets increased to ¥1,024,196,045.60 in Q3 2024 from ¥995,161,763.32 in Q3 2023, representing a rise of 2.9%[24] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥40,989,386.86, showing a substantial increase of 118.73% compared to the previous year[6] - Cash inflow from operating activities totaled ¥154,674,633.06 in the first three quarters of 2024, compared to ¥143,456,307.31 in the same period of 2023, marking an increase of 7.7%[20] - The net cash flow from operating activities for Q3 2024 was ¥40,989,386.86, significantly higher than ¥18,739,814.65 in Q3 2023, indicating a growth of 118.5%[20] - The cash flow from operating activities generated a net amount of ¥26,299,775.21, significantly higher than ¥3,611,423.16 in the previous year[29] - The cash inflow from investment activities reached ¥2,152,847,874.73 in Q3 2024, compared to ¥1,983,947,745.45 in Q3 2023, an increase of 8.5%[21] - The net cash flow generated from investment activities was CNY 69,203,670.43, a significant improvement compared to a net outflow of CNY 316,345,768.66 in the same period last year[30] Shareholder Information - The top ten shareholders hold a combined 84.57% of the total shares, with the largest shareholder owning 34.05%[8] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[9] - The company has not identified any related party transactions among the top shareholders beyond familial relationships[9] Future Outlook - The company plans to continue focusing on product sales growth and reducing R&D expenses to enhance profitability in the future[6] - Future outlook includes continued focus on market expansion and new product development to drive revenue growth[18] - There are no significant new strategies or product developments mentioned in the report[10]